LEADER 03733nam 2201021z- 450 001 9910557692903321 005 20231214133318.0 035 $a(CKB)5400000000044602 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68354 035 $a(EXLCZ)995400000000044602 100 $a20202105d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAdvances in Diagnosis and Therapy of Neuroendocrine Neoplasms 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (144 p.) 311 $a3-03943-745-3 311 $a3-03943-746-1 330 $aThis Special Issue is dedicated to neuroendocrine neoplasms (NENs), a category of malignancy that demonstrates wide clinical heterogeneity, posing major challenges in diagnosis and management. There have been significant advances in the field of NEN genomics, pathology, imaging, and treatment over the past five years. NENs are examples of rare tumours (although their incidence and prevalence are increasing) where international collaborative efforts have allowed the generation of high-level evidence to guide optimal patient-centred care. This issue presents both reviews and original papers to provide comprehensive state-of-the-art understanding of this fascinating disease. 606 $aMedicine$2bicssc 610 $asmall bowel neuroendocrine tumours 610 $apancreatic neuroendocrine tumours 610 $aliver metastases 610 $amidgut 610 $ameta-analysis 610 $aneuroendocrine tumors 610 $acarcinoid heart disease 610 $acarcinoid syndrome 610 $asomatostatin analogues 610 $ametastases 610 $amultidisciplinary 610 $amanagement 610 $aoutcome 610 $agrading 610 $astaging 610 $aneuroendocrine neoplasms 610 $achemotherapy 610 $atemozolomide 610 $ametronomic treatment 610 $asecond-line 610 $aNOTCH 610 $acancer-driven genes 610 $amutational mechanism 610 $agermline mutations 610 $asmall cell lung carcinoma 610 $apancreatic NET 610 $asmall bowel NET 610 $amedullary thyroid carcinoma 610 $amalignant castration-resistant prostatic cells 610 $aquality performance indicators 610 $aQPIs 610 $acancer care 610 $aneuroendocrine tumour 610 $aNETs 610 $amodified Delphi 610 $aCommNETs 610 $apancreatic neuroendocrine neoplasms 610 $aneuroendocrine tumor 610 $along-term functional outcomes 610 $apancreatectomy 610 $adiabetes mellitus 610 $apancreatic exocrine insufficiency 610 $abody mass index 610 $aparenchyma-sparing surgery 610 $aneuroendocrine tumours 610 $acurative surgery 610 $aresection 610 $afollow-up 610 $aguidelines 610 $arelapse 610 $arecurrence 610 $arisk factor 610 $amixed non-neuroendocrine neuroendocrine neoplasms 610 $aMiNENs 610 $amixed adeno-neuroendocrine carcinoma 610 $aMANEC 610 $a2017 WHO classification 610 $a2019 WHO classification 615 7$aMedicine 700 $aSegelov$b Eva$4edt$01311964 702 $aSegelov$b Eva$4oth 906 $aBOOK 912 $a9910557692903321 996 $aAdvances in Diagnosis and Therapy of Neuroendocrine Neoplasms$93030628 997 $aUNINA